Coherus Oncology (CHRS) Non-Current Deferred Tax Liability (2023 - 2026)

Coherus Oncology (CHRS) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (changed 0.0% YoY), and the FY2025 full-year result was $1.1 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q3 2023 to a low of $1.1 million in Q3 2023.
• A 4-year average of $1.1 million and a median of $1.1 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Peak annual rise in Non-Current Deferred Tax Liability reached 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
• Tracing CHRS's Non-Current Deferred Tax Liability over 4 years: stood at $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then changed by 0.0% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
• Business Quant data shows CHRS's Non-Current Deferred Tax Liability at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.